Search results
Results from the WOW.Com Content Network
Buspirone is not effective as a treatment for benzodiazepine withdrawal, barbiturate withdrawal, or alcohol withdrawal. [26]SSRI and SNRI antidepressants such as paroxetine and venlafaxine, respectively, may cause jaw pain/jaw spasm reversible syndrome, although it is not common, and buspirone appears to be successful in treating antidepressant-induced bruxism.
Cerebrovascular accident (stroke); Myocardial infarction (heart attack); Cardiomyopathy; Congestive heart failure; Bradycardia; Dysphoria; Hallucinations; Feelings of ...
Chlordiazepoxide/clidinium bromide is indicated to control emotional and somatic factors in gastrointestinal disorders. [7] It may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.
Desoxyn (methamphetamine hydrochloride) – used to treat attention deficit hyperactivity disorder and exogenous obesity; Dexedrine (dextroamphetamine sulfate) – used to treat attention deficit hyperactivity disorder and narcolepsy
Evidence is not clear for panic disorder [17] and functional gastrointestinal disorders. [18] Tandospirone has also been used to augment antipsychotics in Japan as it improves cognitive and negative symptoms of schizophrenia. [19] Buspirone is being investigated for this purpose as well. [20] [21]
There is a risk of dangerously low blood pressure if people take mianserin along with diazoxide, hydralazine, or nitroprusside. Mianserin can make antihistamines and antimuscarinics have stronger effects. Mianserin should not be taken with apraclonidine, brimonidine, sibutramine, or the combination drug of artemether with lumefantrine. [6]
Gepirone is indicated for the treatment of major depressive disorder (MDD) in adults. [1] Of 15 clinical trials of gepirone for major depressive disorder submitted to the U.S. Food and Drug Administration (FDA), three were excluded for methodological reasons, three were deemed "failed" and "uninformative", seven were deemed negative and did not demonstrate effectiveness, and two were deemed ...
The products recommended for suspension included several 300 mg modified-release bupropion tablets. [197] Following EMA's call for an industry-wide review of medicines for the possible presence of nitrosamines, [198] GlaxoSmithKline paused batch release and distribution of bupropion 150 mg tablets in November 2022. In July 2023, EMA raised the ...